VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
← catalyst calendarNCT06264180 · readout in 1,503 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
81
Countries
France, Germany, Greece +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-11 | actual | When the study began enrolling |
| Primary completion | 2030-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Melanoma
Interventions
- Biological: Vusolimogene Oderparepvec — also filed as VO, RP1
- Biological: Nivolumab — also filed as Opdivo
- Biological: Nivolumab + Relatlimab — also filed as Opdualag
- Biological: Pembrolizumab — also filed as Keytruda
- Drug: Single-agent chemotherapy
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Assessed up to January 2029, approximately 55 months
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed